Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

The deubiquitinating enzyme inhibitor PR-619 is a potent DNA topoisomerase II poison.

Cowell IG, Ling EM, Swan RL, Brooks ML, Austin CA.

Mol Pharmacol. 2019 Sep 12. pii: mol.119.117390. doi: 10.1124/mol.119.117390. [Epub ahead of print]

PMID:
31515282
2.

Would Geriatric Patients Accept Using a Telemedicine Platform for Post ICU-Discharge Follow-Up Visits?

Khairat S, Tirtanadi K, Ottmar P, Gudhe R, Austin CA.

Stud Health Technol Inform. 2019 Aug 21;264:1233-1237. doi: 10.3233/SHTI190423.

PMID:
31438122
3.

Mutations in topoisomerase IIβ result in a B cell immunodeficiency.

Broderick L, Yost S, Li D, McGeough MD, Booshehri LM, Guaderrama M, Brydges SD, Kucharova K, Patel NC, Harr M, Hakonarson H, Zackai E, Cowell IG, Austin CA, Hügle B, Gebauer C, Zhang J, Xu X, Wang J, Croker BA, Frazer KA, Putnam CD, Hoffman HM.

Nat Commun. 2019 Aug 13;10(1):3644. doi: 10.1038/s41467-019-11570-6.

4.

Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.

Atwal M, Swan RL, Rowe C, Lee KC, Lee DC, Armstrong L, Cowell IG, Austin CA.

Mol Pharmacol. 2019 Oct;96(4):475-484. doi: 10.1124/mol.119.117259. Epub 2019 Aug 9.

PMID:
31399497
5.

A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents.

Blower TR, Bandak A, Lee ASY, Austin CA, Nitiss JL, Berger JM.

Nucleic Acids Res. 2019 Sep 5;47(15):8163-8179. doi: 10.1093/nar/gkz579.

PMID:
31287876
6.

Evolution of parental knowledge and efficacy across the pediatric neuropsychological evaluation process.

Austin CA, Gerstle M, Baum KT, Bradley A, LeJeune B, Peugh J, Beebe DW.

Clin Neuropsychol. 2019 May;33(4):743-759. doi: 10.1080/13854046.2018.1497206. Epub 2019 Mar 1.

PMID:
30821626
7.

Association Between Postoperative Delirium and Long-term Cognitive Function After Major Nonemergent Surgery.

Austin CA, O'Gorman T, Stern E, Emmett D, Stürmer T, Carson S, Busby-Whitehead J.

JAMA Surg. 2019 Apr 1;154(4):328-334. doi: 10.1001/jamasurg.2018.5093.

PMID:
30649138
8.

TOP2B: The First Thirty Years.

Austin CA, Lee KC, Swan RL, Khazeem MM, Manville CM, Cridland P, Treumann A, Porter A, Morris NJ, Cowell IG.

Int J Mol Sci. 2018 Sep 14;19(9). pii: E2765. doi: 10.3390/ijms19092765. Review.

9.

Effect of TDP2 on the Level of TOP2-DNA Complexes and SUMOylated TOP2-DNA Complexes.

Lee KC, Swan RL, Sondka Z, Padget K, Cowell IG, Austin CA.

Int J Mol Sci. 2018 Jul 14;19(7). pii: E2056. doi: 10.3390/ijms19072056.

10.

Communication is key: the utility of a revised neuropsychological report format.

Baum KT, von Thomsen C, Elam M, Murphy C, Gerstle M, Austin CA, Beebe DW.

Clin Neuropsychol. 2018 Apr;32(3):345-367. doi: 10.1080/13854046.2017.1413208. Epub 2017 Dec 15.

PMID:
29243544
11.

Rapid Response Events in Hospitalized Patients: Patient Symptoms and Clinician Communication.

Austin CA, Choudhury S, Lincoln T, Chang LH, Cox CE, Weaver MA, Hanson LC, Nelson JE, Carson SS.

J Pain Symptom Manage. 2018 Mar;55(3):946-952. doi: 10.1016/j.jpainsymman.2017.11.086. Epub 2017 Dec 8.

12.

Visualization and Quantification of Topoisomerase-DNA Covalent Complexes Using the Trapped in Agarose Immunostaining (TARDIS) Assay.

Cowell IG, Austin CA.

Methods Mol Biol. 2018;1703:301-316. doi: 10.1007/978-1-4939-7459-7_21.

PMID:
29177750
13.

Topoisomerase II Chromatin Immunoprecipitation.

Smith KA, Cowell IG, Austin CA.

Methods Mol Biol. 2018;1703:183-189. doi: 10.1007/978-1-4939-7459-7_14.

PMID:
29177743
14.

Discovery of Potent Cyclophilin Inhibitors Based on the Structural Simplification of Sanglifehrin A.

Steadman VA, Pettit SB, Poullennec KG, Lazarides L, Keats AJ, Dean DK, Stanway SJ, Austin CA, Sanvoisin JA, Watt GM, Fliri HG, Liclican AC, Jin D, Wong MH, Leavitt SA, Lee YJ, Tian Y, Frey CR, Appleby TC, Schmitz U, Jansa P, Mackman RL, Schultz BE.

J Med Chem. 2017 Feb 9;60(3):1000-1017. doi: 10.1021/acs.jmedchem.6b01329. Epub 2017 Jan 31.

PMID:
28075591
15.

Plant and Human MORC Proteins Have DNA-Modifying Activities Similar to Type II Topoisomerases, but Require One or More Additional Factors for Full Activity.

Manohar M, Choi HW, Manosalva P, Austin CA, Peters JE, Klessig DF.

Mol Plant Microbe Interact. 2017 Feb;30(2):87-100. doi: 10.1094/MPMI-10-16-0208-R. Epub 2017 Feb 3.

16.

Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.

Atwal M, Lishman EL, Austin CA, Cowell IG.

Mol Pharmacol. 2017 Jan;91(1):49-57. Epub 2016 Nov 10.

17.

The Parent Experience of Assessment Scale (PEAS): Development and Relation to Parent Satisfaction.

Austin CA, Finn SF, Keith TZ, Tharinger DJ, Fernando AD.

Assessment. 2018 Oct;25(7):929-941. doi: 10.1177/1073191116666950. Epub 2016 Sep 14.

PMID:
27630203
18.

Long-term outcomes of the bronchial artery embolization are diagnosis dependent.

Pathak V, Stavas JM, Ford HJ, Austin CA, Aris RM.

Lung India. 2016 Jan-Feb;33(1):3-8. doi: 10.4103/0970-2113.173059.

19.

Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.

Lee KC, Bramley RL, Cowell IG, Jackson GH, Austin CA.

Biochem Pharmacol. 2016 Mar 1;103:29-39. doi: 10.1016/j.bcp.2015.12.015. Epub 2016 Jan 12.

20.

Distinct expression patterns for type II topoisomerases IIA and IIB in the early foetal human telencephalon.

Harkin LF, Gerrelli D, Gold Diaz DC, Santos C, Alzu'bi A, Austin CA, Clowry GJ.

J Anat. 2016 Mar;228(3):452-63. doi: 10.1111/joa.12416. Epub 2015 Nov 27.

21.

Distribution and accumulation of 10 nm silver nanoparticles in maternal tissues and visceral yolk sac of pregnant mice, and a potential effect on embryo growth.

Austin CA, Hinkley GK, Mishra AR, Zhang Q, Umbreit TH, Betz MW, E Wildt B, Casey BJ, Francke-Carroll S, Hussain SM, Roberts SM, Brown KM, Goering PL.

Nanotoxicology. 2016 Aug;10(6):654-61. doi: 10.3109/17435390.2015.1107143. Epub 2015 Nov 23.

PMID:
26593872
22.

Genome-wide ChIP-seq analysis of human TOP2B occupancy in MCF7 breast cancer epithelial cells.

Manville CM, Smith K, Sondka Z, Rance H, Cockell S, Cowell IG, Lee KC, Morris NJ, Padget K, Jackson GH, Austin CA.

Biol Open. 2015 Oct 12;4(11):1436-47. doi: 10.1242/bio.014308.

23.

Tools to Promote Shared Decision Making in Serious Illness: A Systematic Review.

Austin CA, Mohottige D, Sudore RL, Smith AK, Hanson LC.

JAMA Intern Med. 2015 Jul;175(7):1213-21. doi: 10.1001/jamainternmed.2015.1679. Review.

24.

Differential Targeting of Human Topoisomerase II Isoforms with Small Molecules.

Mariani A, Bartoli A, Atwal M, Lee KC, Austin CA, Rodriguez R.

J Med Chem. 2015 Jun 11;58(11):4851-6. doi: 10.1021/acs.jmedchem.5b00473. Epub 2015 May 20.

PMID:
25945730
25.

Brief reports: Controlling the survival of human pluripotent stem cells by small molecule-based targeting of topoisomerase II alpha.

Ben-David U, Cowell IG, Austin CA, Benvenisty N.

Stem Cells. 2015 Mar;33(3):1013-9. doi: 10.1002/stem.1888.

26.

Human Tra2 proteins jointly control a CHEK1 splicing switch among alternative and constitutive target exons.

Best A, James K, Dalgliesh C, Hong E, Kheirolahi-Kouhestani M, Curk T, Xu Y, Danilenko M, Hussain R, Keavney B, Wipat A, Klinck R, Cowell IG, Cheong Lee K, Austin CA, Venables JP, Chabot B, Santibanez Koref M, Tyson-Capper A, Elliott DJ.

Nat Commun. 2014 Sep 11;5:4760. doi: 10.1038/ncomms5760.

27.

Alkali metal cation-hexacyclen complexes: effects of alkali metal cation size on the structure and binding energy.

Austin CA, Rodgers MT.

J Phys Chem A. 2014 Jul 24;118(29):5488-500. doi: 10.1021/jp502275q. Epub 2014 Jul 11.

PMID:
24977648
28.

Alkali metal cation interactions with 15-crown-5 in the gas phase: revisited.

Armentrout PB, Austin CA, Rodgers MT.

J Phys Chem A. 2014 Sep 18;118(37):8088-97. doi: 10.1021/jp4116172. Epub 2014 Mar 6.

PMID:
24559535
29.

Utilization of rapid response resources and outcomes in a comprehensive cancer center*.

Austin CA, Hanzaker C, Stafford R, Mayer C, Culp L, Lin FC, Chang L.

Crit Care Med. 2014 Apr;42(4):905-9. doi: 10.1097/CCM.0000000000000098.

PMID:
24361969
30.

The role of topoisomerase II beta on breakage and proximity of RUNX1 to partner alleles RUNX1T1 and EVI1.

Smith KA, Cowell IG, Zhang Y, Sondka Z, Austin CA.

Genes Chromosomes Cancer. 2014 Feb;53(2):117-28. doi: 10.1002/gcc.22124. Epub 2013 Nov 5.

31.

A high-throughput fluorescence anisotropy-based assay for human topoisomerase II β-catalyzed ATP-dependent supercoiled DNA relaxation.

Shapiro AB, Austin CA.

Anal Biochem. 2014 Mar 1;448:23-9. doi: 10.1016/j.ab.2013.11.029. Epub 2013 Dec 3.

32.

Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the α isoform.

Bau JT, Kang Z, Austin CA, Kurz EU.

Mol Pharmacol. 2014 Feb;85(2):198-207. doi: 10.1124/mol.113.088963. Epub 2013 Nov 12.

PMID:
24220011
33.

Alpha, beta-unsaturated lactones 2-furanone and 2-pyrone induce cellular DNA damage, formation of topoisomerase I- and II-DNA complexes and cancer cell death.

Calderón-Montaño JM, Burgos-Morón E, Orta ML, Pastor N, Austin CA, Mateos S, López-Lázaro M.

Toxicol Lett. 2013 Sep 12;222(1):64-71. doi: 10.1016/j.toxlet.2013.07.007. Epub 2013 Jul 15.

PMID:
23867916
34.

Time to follow commands remains the most useful injury severity variable for predicting WeeFIM® scores 1 year after paediatric TBI.

Austin CA, Slomine BS, Dematt EJ, Salorio CF, Suskauer SJ.

Brain Inj. 2013;27(9):1056-62. doi: 10.3109/02699052.2013.794964. Epub 2013 Jun 19.

35.

Guanidine-reactive agent phenylglyoxal induces DNA damage and cancer cell death.

Calderón-Montaño JM, Burgos-Morón E, Orta ML, Pastor N, Perez-Guerrero C, Austin CA, Mateos S, López-Lázaro M.

Pharmacol Rep. 2012;64(6):1515-25.

36.

MRE11 facilitates the removal of human topoisomerase II complexes from genomic DNA.

Lee KC, Padget K, Curtis H, Cowell IG, Moiani D, Sondka Z, Morris NJ, Jackson GH, Cockell SJ, Tainer JA, Austin CA.

Biol Open. 2012 Sep 15;1(9):863-73. doi: 10.1242/bio.20121834. Epub 2012 Jul 11.

37.

Do transcription factories and TOP2B provide a recipe for chromosome translocations in therapy-related leukemia?

Cowell IG, Austin CA.

Cell Cycle. 2012 Sep 1;11(17):3143-4. doi: 10.4161/cc.21477. Epub 2012 Aug 16. No abstract available.

38.

The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage.

Wendorff TJ, Schmidt BH, Heslop P, Austin CA, Berger JM.

J Mol Biol. 2012 Dec 7;424(3-4):109-24. doi: 10.1016/j.jmb.2012.07.014. Epub 2012 Jul 25.

39.

Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents.

Cowell IG, Austin CA.

Int J Environ Res Public Health. 2012 Jun;9(6):2075-91. doi: 10.3390/ijerph9062075. Epub 2012 May 31. Review.

40.

Index of suspicion. Case 1: Infant who has respiratory distress. Case 2: Abnormal behavior, seizures, and altered sensorium in a 7-year-old boy. Case 3: Fever and dysphagia in a 4-year-old girl.

Sulton-Villavasso C, Austin CA, Patra KP, Sankararaman S, Ray M, May R, Bordley C.

Pediatr Rev. 2012 Jun;33(6):279-84. doi: 10.1542/pir.33-6-279. No abstract available. Erratum in: Pediatr Rev. 2012 Oct;33(10):468.

PMID:
22659261
41.

Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity.

Cowell IG, Sondka Z, Smith K, Lee KC, Manville CM, Sidorczuk-Lesthuruge M, Rance HA, Padget K, Jackson GH, Adachi N, Austin CA.

Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):8989-94. doi: 10.1073/pnas.1204406109. Epub 2012 May 21.

42.

Therapeutic assessment with an adolescent: choosing connections over substances.

Austin CA, Krumholz LS, Tharinger DJ.

J Pers Assess. 2012;94(6):571-85. doi: 10.1080/00223891.2012.670679. Epub 2012 Apr 4.

PMID:
22475356
43.

Distribution of silver nanoparticles in pregnant mice and developing embryos.

Austin CA, Umbreit TH, Brown KM, Barber DS, Dair BJ, Francke-Carroll S, Feswick A, Saint-Louis MA, Hikawa H, Siebein KN, Goering PL.

Nanotoxicology. 2012 Dec;6:912-22. doi: 10.3109/17435390.2011.626539. Epub 2011 Oct 24.

PMID:
22023110
44.

Histone deacetylase inhibition redistributes topoisomerase IIβ from heterochromatin to euchromatin.

Cowell IG, Papageorgiou N, Padget K, Watters GP, Austin CA.

Nucleus. 2011 Jan-Feb;2(1):61-71. doi: 10.4161/nucl.2.1.14194.

45.

Green tea constituents (-)-epigallocatechin-3-gallate (EGCG) and gallic acid induce topoisomerase I- and topoisomerase II-DNA complexes in cells mediated by pyrogallol-induced hydrogen peroxide.

López-Lázaro M, Calderón-Montaño JM, Burgos-Morón E, Austin CA.

Mutagenesis. 2011 Jul;26(4):489-98. doi: 10.1093/mutage/ger006. Epub 2011 Mar 7.

PMID:
21382914
46.

Dynamic expression of two thrombospondins during axolotl limb regeneration.

Whited JL, Lehoczky JA, Austin CA, Tabin CJ.

Dev Dyn. 2011 May;240(5):1249-58. doi: 10.1002/dvdy.22548. Epub 2011 Feb 1.

47.

The impact of the C-terminal domain on the interaction of human DNA topoisomerase II α and β with DNA.

Gilroy KL, Austin CA.

PLoS One. 2011 Feb 16;6(2):e14693. doi: 10.1371/journal.pone.0014693.

48.

Tubulin tyrosine ligase-like genes ttll3 and ttll6 maintain zebrafish cilia structure and motility.

Pathak N, Austin CA, Drummond IA.

J Biol Chem. 2011 Apr 1;286(13):11685-95. doi: 10.1074/jbc.M110.209817. Epub 2011 Jan 24.

49.

Poly(ADP-ribose) polymerases PARP1 and PARP2 modulate topoisomerase II beta (TOP2B) function during chromatin condensation in mouse spermiogenesis.

Meyer-Ficca ML, Lonchar JD, Ihara M, Meistrich ML, Austin CA, Meyer RG.

Biol Reprod. 2011 May;84(5):900-9. doi: 10.1095/biolreprod.110.090035. Epub 2011 Jan 12.

50.

An overview of the visualisation and quantitation of low and high MW DNA adducts using the trapped in agarose DNA immunostaining (TARDIS) assay.

Cowell IG, Tilby MJ, Austin CA.

Mutagenesis. 2011 Mar;26(2):253-60. doi: 10.1093/mutage/geq094. Epub 2010 Nov 10. Review.

PMID:
21068206

Supplemental Content

Loading ...
Support Center